Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | The use of ctDNA in identifying post-surgical CRC residual disease status

Yoshiaki Nakamura, MD, PhD, National Cancer Center Hospital East, Kashiwa, Japan, explains the results of the GALAXY arm of the ongoing CIRCULATE-Japan trial (UMIN000039205) considering circulating tumor DNA (ctDNA) as a useful indicator in colorectal cancer (CRC). Disease-free survival (DFS) positively correlated with ctDNA levels and when stratifying molecular residual disease (MRD) groups using ctDNA, patients who were MRD-positive significantly benefitted from adjuvant chemotherapy (ACT), whereas patients who were MRD-negative did not. This presents ctDNA as a beneficial indicator to identify patients who are likely to benefit from post-surgical ACT. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.